KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
about
KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas.The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors.Accuracy of Cytology Specimen and Needle Core Biopsies for Detection of KRAS Mutation in Non-Small Cell Carcinoma: Comparison With Resection Specimen.Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
P2860
KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
KRAS status analysis and anti- ...... fancy or a clinical necessity?
@en
KRAS status analysis and anti- ...... fancy or a clinical necessity?
@nl
type
label
KRAS status analysis and anti- ...... fancy or a clinical necessity?
@en
KRAS status analysis and anti- ...... fancy or a clinical necessity?
@nl
prefLabel
KRAS status analysis and anti- ...... fancy or a clinical necessity?
@en
KRAS status analysis and anti- ...... fancy or a clinical necessity?
@nl
P2093
P2860
P356
P1476
KRAS status analysis and anti- ...... fancy or a clinical necessity?
@en
P2093
E Lopez-Crapez
P2860
P2888
P304
1074-5; author reply 1076-7
P356
10.1038/SJ.BJC.6605582
P407
P577
2010-02-16T00:00:00Z